For instance, a significant decrease in IL-10, a key cytokine released by tumor cells to suppress the host immune function by inhibition of dendritic cell differentiation and maturation in vitro [37], was observed following combination treatment of 1,4-dihydroxy quininib with Bevacizumab. The gene discussed is IL10; the disease is neoplasm.